Paper42182829
Sodium-Glucose Cotransporter 2 Inhibitors in Lupus Nephritis and ANCA-Associated Vasculitis: Unmet Needs to be Addressed.
Vajgel G and 2 others. Glomerular Dis, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Sodium-Glucose Cotransporter 2 Inhibitors in Lupus Nephritis and ANCA-Associated Vasculitis: Unmet Needs to be Addressed. Papers, record 42182829. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42182829
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Sodium-Glucose Cotransporter 2 Inhibitors in Lupus Nephritis and ANCA-Associated Vasculitis: Unmet Needs to be Addressed.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References163
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36931466 | Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis. | Clin Res Hepatol Gastroenterol | 2023 | https://conductscience.org/library/papers/36931466 | PubMed |
| 2 | 37881002 | EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association-Immunonephrology Working Group (ERA-IWG) perspective. | Nephrol Dial Transplant | 2024 | https://conductscience.org/library/papers/37881002 | PubMed |
| 3 | 41005568 | Mineralocorticoid receptor inhibition in parietal epithelial cells prevents focal segmental glomerulosclerosis and crescentic glomerulonephritis. | Kidney Int | 2025 | https://conductscience.org/library/papers/41005568 | PubMed |
| 4 | 37793348 | Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis. | Am J Nephrol | 2024 | https://conductscience.org/library/papers/37793348 | PubMed |
| 5 | 11466120 | Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. | JAMA | 2001 | https://conductscience.org/library/papers/11466120 | PubMed |
| 6 | 41324239 | Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial. | Nephrol Dial Transplant | 2026 | https://conductscience.org/library/papers/41324239 | PubMed |
| 7 | 40398102 | Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: A national cohort study. | Semin Arthritis Rheum | 2025 | https://conductscience.org/library/papers/40398102 | PubMed |
| 8 | 35069210 | Dapagliflozin Alleviates Renal Fibrosis by Inhibiting RIP1-RIP3-MLKL-Mediated Necroinflammation in Unilateral Ureteral Obstruction. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/35069210 | PubMed |
| 9 | 38865122 | Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus. | JAMA Netw Open | 2024 | https://conductscience.org/library/papers/38865122 | PubMed |
| 10 | 38186886 | Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial. | Clin Kidney J | 2024 | https://conductscience.org/library/papers/38186886 | PubMed |
| 11 | 29029294 | Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. | Rheumatology (Oxford) | 2018 | https://conductscience.org/library/papers/29029294 | PubMed |
| 12 | 33105763 | Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33105763 | PubMed |
| 13 | 34560555 | Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. | Biomed Pharmacother | 2021 | https://conductscience.org/library/papers/34560555 | PubMed |
| 14 | 32083798 | Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. | J Diabetes Investig | 2020 | https://conductscience.org/library/papers/32083798 | PubMed |
| 15 | 36351458 | Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. | Lancet | 2022 | https://conductscience.org/library/papers/36351458 | PubMed |
| 16 | 35363499 | 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | Circulation | 2022 | https://conductscience.org/library/papers/35363499 | PubMed |
| 17 | 30089717 | SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. | JCI Insight | 2018 | https://conductscience.org/library/papers/30089717 | PubMed |
| 18 | 34850160 | Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. | Nephrol Dial Transplant | 2022 | https://conductscience.org/library/papers/34850160 | PubMed |
| 19 | 33636561 | Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and Meta-analysis. | Int Immunopharmacol | 2021 | https://conductscience.org/library/papers/33636561 | PubMed |
| 20 | 37289399 | The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers. | Int Urol Nephrol | 2023 | https://conductscience.org/library/papers/37289399 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42593596 | Immunometabolic Effects of SGLT2 Inhibitors on the Th17/Treg Axis: Mechanisms, Evidence, and Implications for Therapeutic Repurposing. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42593596 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SLC5A2 | 6524 | PubTator's text mining | https://conductscience.org/library/genes/6524 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42182829
GET https://conductscience.org/api/papers/v1/42182829/references?page=2